Paid Clinical Trials Aberdeen

Discover 8 paid clinical trials in Aberdeen, South Dakota. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 8

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

for

Fallopian Tube Endometrioid Adenocarcinoma,

2 locations in Aberdeen

Sponsor: NRG Oncology

Sex: All

Age: 18+

Code: NCT06580314

Phase3, Recruiting

Avera Cancer Sequencing and Analytics Protocol (ASAP)

for

Cancer, Cancer Diagnosis, Early Detection of Cancer,

1 location in Aberdeen

Sponsor: Avera McKennan Hospital & University Health Center

Sex: All

Age: 18+

Code: NCT05142033

Recruiting

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

for

Plasma Cell Myeloma

2 locations in Aberdeen

Sponsor: SWOG Cancer Research Network

Sex: All

Age: 0+

Code: NCT05561387

Phase3, Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for

Pancreatic Acinar Cell Carcinoma,

1 location in Aberdeen

Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04858334

Phase2, Recruiting

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

for

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer,

1 location in Aberdeen

Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06065748

Phase3, Recruiting

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

for

Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma,

1 location in Aberdeen

Sponsor: National Cancer Institute (NCI)

Sex: Female

Age: 18+

Code: NCT05256225

Phase3, Recruiting

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

for

Breast Cancer, Early Breast Cancer

1 location in Aberdeen

Sponsor: AstraZeneca

Sex: All

Age: 18 - 70+

Code: NCT05952557

Phase3, Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

for

Breast Cancer, Early Breast Cancer

1 location in Aberdeen

Sponsor: AstraZeneca

Sex: All

Age: 18 - 70+

Code: NCT05774951

Phase3, Recruiting

Paid Clinical Trials Aberdeen

Filter results

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Avera Cancer Sequencing and Analytics Protocol (ASAP)

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Interested in new trials?

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy